Corbus Pharmaceuticals (CRBP) RBC Capital Markets Global Healthcare Conference 2026 summary

Key data presentations and expectations for ASCO

• ASCO will feature updated monotherapy data for CRB-701 in cervical and head and neck cancers, including confirmed overall response rates (cORR), duration of response (DOR), and progression-free survival (PFS).

• Stratification by HPV status and anatomical subtypes in head and neck cancer will be presented, clarifying the target population for future studies.

• Comparative analysis with PADCEV and other EGFR bispecifics highlights the importance of Nectin-4 enrichment and HPV status in response rates.

• Regulatory and clinical trial design will be informed by these data, with a randomized study in head and neck cancer starting this summer.

• Registrational study in cervical cancer is planned for next year, with standard of care comparators including Tivdak and chemotherapy.

Clinical development plans and regulatory strategy

• Head and neck cancer trial will compare CRB-701 to physician's choice in second-line patients, using ORR as an accelerated approval endpoint.

• Study design and population will be finalized after ASCO data, with clarity on inclusion/exclusion of cetuximab based on HPV status.

• Early next year, initial efficacy data for CRB-701 plus pembrolizumab in frontline head and neck cancer will be available.

• Cervical cancer study will use Tivdak or chemotherapy as comparators, with a focus on improved tolerability and efficacy.

• Commercial prospects depend on differentiation from existing therapies, especially in tolerability and response rates.

Safety and competitive landscape for CRB-701

• Ocular toxicity profile is similar to Tivdak and ELAHERE, but with fewer severe adverse events compared to BLENREP.

• CRB-701 may offer improved tolerability over Tivdak, which is limited by peripheral neuropathy, severe skin events, and bleeding.

• Higher potency observed in previous data sets suggests potential to outperform Tivdak in cervical cancer.

• In head and neck cancer, the competitive landscape is evolving, with uncertainty around the all-comers label for Genmab's peto.

• Strategic decisions by competitors may shift focus to HPV-negative populations.